top of page
CYTORA LOGO

We are participating in the Virtual Partnering event at RESI Boston 2025 on 17th, 18th and 23rd of June.

11 June 2025

Looking forward to showcasing our vision to improve and save the lives of millions of people worldwide suffering from multifactorial and challenging diseases through our unique patented human oral mucosa neural crest stem cell platform technology.

Cytora bottom logo

Cytora’s patented platform technology is based on the discovery of a novel and unique stem cell population in the human oral mucosa (hOMSC), the origin of which is the embryonic nervous system. hOMSC are endowed with properties of neural crest, neural and mesenchymal stem cells. Cytora’s products are allogeneic, off-the-shelf, easily scalable, with a very competitive cost of goods (COG). The products were found to be safe and effective in early phase clinical trials in two indications: Diabetic Foot Ulcers (DFU) and Multiple System Atrophy (MSA).

Our products have high potential for treating complicated multifactorial diseases such as chronic and neurodegenerative diseases, incurable wounds and autoimmune diseases.

MENU

ABOUT US

TECHNOLOGY

PIPELINE

TEAM

PUBLICATIONS

CONTACT US

Dividing blue line

CONTACT US

info@cytorastem.com

© 2022 Cytora. All rights reserved.

bottom of page